Related Experiment Video
Updated: Jun 26, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives
Megan Montoya1,2, Marco Gallus1,2, Su Phyu1,2
1Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
Abstract:
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median overall survival of less than 2 years and a nearly 100% mortality rate under standard therapy that consists of surgery followed by combined radiochemotherapy. Therefore, new therapeutic strategies are urgently needed. The success of chimeric antigen receptor (CAR) T cells in hematological cancers has prompted preclinical and clinical investigations into CAR-T-cell treatment for GBM. However, recent trials have not demonstrated any major success. Here, we delineate existing challenges impeding the effectiveness of CAR-T-cell therapy for GBM, encompassing the cold (immunosuppressive) microenvironment, tumor heterogeneity, T-cell exhaustion, local and systemic immunosuppression, and the immune privilege inherent to the central nervous system (CNS) parenchyma. Additionally, we deliberate on the progress made in developing next-generation CAR-T cells and novel innovative approaches, such as low-intensity pulsed focused ultrasound, aimed at surmounting current roadblocks in GBM CAR-T-cell therapy.
Insights
Chimeric antigen receptor (CAR) T-cell therapy faces significant challenges in treating glioblastoma (GBM), including the tumor microenvironment and immune suppression. New strategies are being developed to overcome these hurdles for improved GBM treatment outcomes.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cellular Therapy
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
- Current standard treatments (surgery + radiochemotherapy) offer limited survival benefits.
- Chimeric antigen receptor (CAR) T-cell therapy shows promise but faces obstacles in GBM.
Purpose of the Study:
- To identify key challenges hindering CAR T-cell therapy efficacy in glioblastoma.
- To explore advancements in next-generation CAR T-cells and innovative therapeutic approaches for GBM.
Main Methods:
- Review and analysis of existing literature on CAR T-cell therapy for GBM.
- Identification of biological and immunological barriers to treatment success.
- Exploration of novel therapeutic strategies and technologies.
Main Results:
- Significant challenges include the immunosuppressive GBM microenvironment, tumor heterogeneity, T-cell exhaustion, and central nervous system (CNS) immune privilege.
- Next-generation CAR T-cells and combination therapies are under development.
- Innovative approaches like focused ultrasound show potential.
Conclusions:
- Overcoming the multifaceted barriers in the GBM tumor microenvironment is critical for successful CAR T-cell therapy.
- Advancements in CAR T-cell engineering and combination strategies offer new hope for treating glioblastoma.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
05:22Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy